Affiliated Hospital To Academy Of Military Medical Sciences
Clinical trials sponsored by Affiliated Hospital To Academy Of Military Medical Sciences, explained in plain language.
-
Double-barreled CAR-T takes aim at hard-to-treat blood cancers
Disease control Not yet recruitingThis early-phase study tests a new type of cell therapy that targets two markers (BCMA and CD70) on cancer cells. It is designed for people with high-risk plasma cell neoplasms, including multiple myeloma. The main goals are to check safety and find the right dose, while also mea…
Phase: EARLY_PHASE1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated May 17, 2026 03:28 UTC
-
Double-barreled cell therapy takes aim at hard-to-treat blood cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment using a patient's own immune cells, engineered to attack two cancer targets (CD19 and BCMA), for people with certain blood cancers (like multiple myeloma or lymphoma) that have returned or stopped responding to standard therapy. About …
Phase: EARLY_PHASE1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated May 17, 2026 03:27 UTC
-
Nanobody CAR-T therapy takes on resistant lymphoma in early trial
Disease control Not yet recruitingThis early-phase study tests a new type of CAR-T cell therapy that uses nanobodies to target two markers (CD19 and CD20) on lymphoma cells. It aims to see if the treatment is safe and find the best dose in 20 people with relapsed or refractory B-cell lymphoma. The therapy is give…
Phase: EARLY_PHASE1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated May 11, 2026 20:38 UTC